Tirzepatide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and NICE (England), among others, recommended or restricted tirzepatide, while AIFA (Italy), AOTMIT (Poland) and CIPM (Spain), among others, did not recommend it.
The record spans 3.8 years, opening at AWMSG (Wales) on 30 Sep 2022 and running to 2026.
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 23 of 24 records date from 2023 or later.
Against its own class, tirzepatide is an outlier: 53% of its decisive outcomes were positive, where molecules sharing ATC class A10B average 77%.
7 distinct indication wordings are recorded for tirzepatide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tirzepatide, on 30 Sep 2022; PHARMAC (New Zealand) did not open a file until 8 Dec 2025 — a wide spread of 3.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
8 of the 12 agencies here assessed tirzepatide more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
tirzepatide has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tirzepatide reads 9 not recommended, 6 recommended, 4 restricted and 2 appraised, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 6 May 2026 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| ZIN (Netherlands) | 19 Mar 2026 | Advies - uitbreiding vergoedingsvoorwaarden tirzepatide (Mounjaro®) voor mensen met diabetes en een zeer hoog risico op … | conditions amended | source |
| CIPM (Spain) | 17 Dec 2025 | Indicaciones terapéuticas autorizadas: Diabetes mellitus tipo 2 Mounjaro está indicado para el tratamiento de adultos co… | not financed by the SNS · art. 92 d | source |
| PHARMAC (New Zealand) | 8 Dec 2025 | Diabetes mellitus, type 2, insufficiently controlled | PTAC advice: Medium | source |
| AOTMIT (Poland) | 22 Oct 2025 | Mounjaro reimbursement recommendation | not recommended | source |
19 further decisions for tirzepatide, across 10 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- dapagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- saxagliptin — divergent outcome (not recommended vs recommended) on a shared indication
- vildagliptin — divergent outcome (not recommended vs recommended) on a shared indication
- empagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- pioglitazone — divergent outcome (not recommended vs recommended) on a shared indication
- dulaglutide — divergent outcome (not recommended vs recommended) on a shared indication
Coverage: 24 decisions for tirzepatide from 12 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.